A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E (ROTAVAC)

Bharat Biotech

Status and phase

Unknown

Phase 3

Conditions

Viral Gastroenteritis Due to Rotavirus

Treatments

Biological: Placebo

Biological: ORV 116E

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01305109

Clinical Trials Registry-India (Registry Identifier)

BBIL/ROTA/021

Details and patient eligibility

About

Full description

The trial is a phase III randomized, double-blind, placebo-controlled trial with the primary objective of evaluating the efficacy of three doses of ORV 116E, 10^5.0 FFU, against severe rotavirus gastroenteritis, in comparison with a placebo in India. The clinical trial is not a global trial. Three administrations of ORV 116E will be co-administered with childhood vaccines (which will include vaccines against diphtheria, pertussis, tetanus, Haemophilus influenzae B and Hepatitis B and OPV) at 6 to 7 weeks, greater than or equal to 10 weeks and greater than or equal to 14 weeks of age. 6800 subjects will be enrolled in three sites - Delhi, Pune (Maharashtra) and Vellore (Tamil Nadu) and followed up till the age of 2 years (24 months + up to 14 days). Multiple trial sites are included to ensure greater demographic distribution to obtain evidence of cross immunity and quicker recruitment of the necessary number of subjects. The subjects to be included from these sites would be representative of the population of India.

The protocol has been reviewed by the institutional review boards of the Society for Applied Studies (New Delhi), KEM Hospital Research Centre (Pune), Christian Medical College (Vellore). Ethics clearance has also been obtained from the Department of Biotechnology, Government of India and Western Institutional Review Board.

Enrollment

6,800 estimated patients

Sex

All

Ages

6 to 7 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

At least one parent(s) or legally acceptable representative's consent for participation and are able to understand study procedures
Subjects aged 6 to 7 weeks at recruitment
No plans to move in the next 24 months

Exclusion criteria

Administration of rotavirus vaccine in the past
Presence of any illness requiring hospital referral (temporary exclusion)
Known case of immunodeficiency disease, known HIV positive
Known case of chronic gastroenteritis disease
Any other conditions which in the judgment of the investigator warrant exclusion (e.g. no exclusion criteria but seems "ill", investigators suspects neglect)
Diarrhea on the day of enrollment (temporary exclusion)